Goodness Growth Holdings™ Subsidiary Resurgent Biosciences Launches First IRB-Approved Research Study on Entheogens & Psychedelic Experiences
Resurgent Biosciences, a subsidiary of Goodness Growth Holdings (GDNS), is tapping into the spiritual and cultural side of psychedelics to develop a better approach to psychedelic therapy.
The company is launching a study on the naturalistic use of entheogens through a partnership with Flor da Jurema, a temple community in Brazil where visitors can take part in spiritual experiences with traditional plant medicines.
The study, which was just approved by an independent Institutional Review Board, will survey 100 adults who have participated in entheogen therapy centers or psychedelic retreats in the last five years.
The goal is to get a sense of their intentions, motivations, experiences, demographics, and willingness to participate in entheogen research in the future and use the findings to create more positive, long-lasting results from psychedelic-assisted therapies.